Insider Selling: Disc Medicine (NASDAQ:IRON) Insider Sells 5,731 Shares of Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider William Jacob Savage sold 5,731 shares of the business’s stock in a transaction on Monday, April 13th. The stock was sold at an average price of $66.38, for a total transaction of $380,423.78. Following the transaction, the insider directly owned 79,480 shares of the company’s stock, valued at approximately $5,275,882.40. This represents a 6.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

William Jacob Savage also recently made the following trade(s):

• On Monday, March 2nd, William Jacob Savage sold 7,378 shares of Disc Medicine stock. The stock was sold at an average price of $65.88, for a total transaction of $486,062.64.
• On Tuesday, February 17th, William Jacob Savage sold 3,256 shares of Disc Medicine stock. The stock was sold at an average price of $62.86, for a total transaction of $204,672.16.

Disc Medicine Stock Performance

Disc Medicine stock traded down $0.30 on Wednesday, reaching $70.18. 300,163 shares of the stock were exchanged, compared to its average volume of 660,190. The stock has a market cap of $2.68 billion, a PE ratio of -11.72 and a beta of 0.91. The company has a current ratio of 21.94, a quick ratio of 21.94 and a debt-to-equity ratio of 0.04. Disc Medicine, Inc. has a twelve month low of $39.20 and a twelve month high of $99.50. The firm has a fifty day moving average price of $64.99 and a two-hundred day moving average price of $76.18.

Disc Medicine (NASDAQ:IRON) last released its earnings results on Thursday, February 26th. The company reported ($1.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.69) by $0.07. The firm had revenue of ($19.88) million for the quarter, compared to analyst estimates of $0.15 million. Sell-side analysts anticipate that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on IRON. Truist Financial dropped their price objective on shares of Disc Medicine from $114.00 to $83.00 and set a “buy” rating on the stock in a report on Friday, February 27th. TD Cowen restated a “buy” rating on shares of Disc Medicine in a report on Friday, December 19th. Cantor Fitzgerald dropped their price objective on shares of Disc Medicine from $153.00 to $125.00 and set an “overweight” rating on the stock in a report on Tuesday, February 17th. Morgan Stanley set a $75.00 price objective on shares of Disc Medicine in a report on Tuesday, February 17th. Finally, Stifel Nicolaus dropped their price objective on shares of Disc Medicine from $125.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $104.80.

Institutional Trading of Disc Medicine

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. increased its stake in Disc Medicine by 3,329.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 357,836 shares of the company’s stock valued at $28,416,000 after acquiring an additional 347,403 shares during the period. TimesSquare Capital Management LLC bought a new stake in Disc Medicine in the third quarter valued at about $12,038,000. Y Intercept Hong Kong Ltd increased its stake in Disc Medicine by 361.4% in the third quarter. Y Intercept Hong Kong Ltd now owns 43,287 shares of the company’s stock valued at $2,860,000 after acquiring an additional 33,905 shares during the period. Atle Fund Management AB increased its stake in Disc Medicine by 85.3% in the third quarter. Atle Fund Management AB now owns 45,690 shares of the company’s stock valued at $3,019,000 after acquiring an additional 21,038 shares during the period. Finally, Hudson Bay Capital Management LP bought a new stake in Disc Medicine in the third quarter valued at about $6,752,000. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.